Abstract 418P
Background
The treatment of NSCLC has changed drastically in the last decade since the discovery of biomarkers like EGFR, ALK, ROS etc. Most common EGFR mutations in NSCLC include del19 and exon 21 L858R mutations. However, approximately 10% of NSCLC patients have uncommon EGFR mutations (complex indels undetected by single gene testing, missense mutations involving G719, L861, & S768 codons, and exon 20 insertions) which do not respond as well to TKIs. Thus, it is very important to understand type of EGFR mutations in clinical practice. This retrospective study reviews prevalence of these mutations in an Indian NSCLC cohort along with the clinicopathologic characteristics.
Methods
A total of 470 EGFR mutated NSCLC were analyzed. Of these, cases harboring uncommon EGFR mutations (n=49), were reviewed retrospectively, for clinicopathologic features. This study was approved by ethics committee of the institute.
Results
Of the 470 cases, 49 (10.42%) were found to have uncommon EGFR mutations. The median age was 66 years (35-87years). Almost equal sex predilection with 25 (51%) males and 24 (49%) females. Among these, 39 (79.6%) were never smokers, 7 (14.3%) smokers. Intrathoracic metastases in form of lung-lung spread were noted in 20 patients (40.8%); lung-pleura in 38 (77.6%) patients. Extrathoracic metastases noted include brain (n=18, 36.7%), liver (n=14, 28.6%), bone (n=25, 51%), &adrenals (n=4, 8.2%). Thirteen cases had dual mutations in EGFR including L861Q and G719X in 3 patients, G719X and S768I in 1 patient, L858R and S768I in 1 patient, del19 and L8585R in 1 patient and additional T790M with del 19 and L858R in 4 and 2 patients respectively. The mutation profile of patients with single mutations included 4 cases of L861, 5 cases of S768,8 cases of G719, 1 case of exon 18 insertion and 14 cases of exon 20 insertion. Patients with L861Q were males (p<0.047) and never smokers (p<0.018). Exon 20 insertions were more common in females (p<0.024). Nine patients received TKI treatment; Seven were treated with afatinib and two with osimertinib (one patient had T790M mutation, the other had S768I mutation).
Conclusions
Rare and dual EGFR mutations are a heterogeneous group with distinct clinical features. This study highlights the same in an Indian cohort of EGFR mutated NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ullas Batra.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session